HVIIUHennessy Capital Investment Corp. VII
The schedule
- Wed30Sep
By late September 2026, HVIIU may announce a letter of intent or definitive business combination; a credible target in a favored growth theme with reasonable valuation could re-rate the units from $10.90 toward $11.60, while a weak sector, aggressive valuation or small float could drive heavy redemption risk and push the price down toward $11.60 as arbitrage capital exits.
- Sun15Nov
Assuming a transaction is announced, detailed PIPE and backstop financing terms around mid-November will clarify how much cash the combined company retains; strong institutional demand at or above $10.00 could lift HVIIU from $9.90 back toward $10.60, while a highly dilutive structure, deep discounts or small PIPE size would reinforce redemption fears and could push the stock toward $10.60.
- Fri15Jan
Once the S-4 for the HVIIU merger becomes effective and the proxy is cleared, updated projections, risk factors and fairness analysis will be public; if disclosures reinforce achievable forecasts and no major regulatory issues emerge, the stock could recover from $9.10 toward $10.10, whereas aggressive assumptions, governance concerns or negative regulatory commentary could cap interest and drag shares toward $10.10.
- Mon15Mar
At the merger vote in March 2027, public shareholders will decide whether to approve the deal and whether to redeem; low redemptions and strong support for the transaction could re-rate HVIIU from $8.70 toward $11.20 as a fully funded operating company, while heavy redemptions, a failed vote or last-minute deal revisions could leave shares near $8.00 as the SPAC faces liquidation risk or a materially smaller float.
- Wed12May
- Wed11Aug
Past
- Wed12Aug
- Wed13May
Q1 2026 10-Q will update trust value per share, interest income and any use of working capital; with HVIIU trading at $10.74 near its 52-week range and RSI above 70, a clean trust mark and no unexpected expenses could modestly support the unit price, while any indication of faster cash burn or uncertainty on extension terms could pressure it back toward $10.90.